SITE008-0065

SITE008 (KOR) › SITE008-0065

SITE008-0065

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2025-11-10

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 125); relationship: not assessed

mild assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-06-06 (study day 12); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.